Interview, Podcast
The cutting edge of anti-ageing science | Venki Ramakrishnan
- The number of centenarians is projected to rise due to healthcare and lifestyle improvements, while supercentenarian growth is expected to plateau, suggesting a hard biological limit of 110 to 120 years that requires intervention to surpass.
- Eliminating major age-related diseases is predicted to yield only an additional 15 years of life, as aging itself will continue to drive disease risk and eventual mortality around age 110 to 120 even without cancer or heart disease.
- Significant lifespan extension, potentially doubling current limits, is forecasted to depend on major breakthroughs in aging research, specifically regarding the brain, which remains a complex problem with no current solution.
- Clinical trials for RNA interference therapies targeting Alzheimer's are anticipated within the next few years, while senolytic drug trials are expected to be necessary to prove safety and specificity, with viable interventions anticipated due to current investment levels.
- Metformin trials are ongoing to assess anti-aging benefits, whereas resveratrol is not expected to extend lifespan based on recent large-scale data; rapamycin requires establishing a specific dosage sweet spot to avoid immunosuppression.
- Yamanaka factor therapies are expected to undergo extensive animal testing and require defined dosages and safety measures before human clinical trials, despite their potential to reverse aging, with cancer risk remaining a primary concern.
- Doubling human lifespan is contingent on overcoming brain aging, which is identified as a critical barrier, and while nutrient sensing pathways and senescent cell removal may extend healthy years, their impact on maximum lifespan remains uncertain.
- Societal shifts including a larger older population fraction and potential job market competition with younger workers are anticipated if fertility rates drop while longevity increases, creating questions of generational fairness.
- Economic inequality is expected to widen significantly if anti-aging treatments initially remain accessible only to the wealthy, potentially creating two classes of citizens unless universal health care access is secured.
- Economic expansion from increased workforce participation is not guaranteed, as productivity gains may be offset by automation and AI, and older workers may need to adapt to different roles rather than retaining high-stakes positions held in youth.
- Widespread adoption of anti-aging technology is expected to occur regardless of societal preference once available, driven by individual demand, though life expectancy gaps between rich and poor are projected to diverge without preventive health measures.